Last reviewed · How we verify
Boostrix TM
Boostrix is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, and pertussis (whooping cough) pathogens.
Boostrix is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, and pertussis (whooping cough) pathogens. Used for Booster vaccination against diphtheria, tetanus, and pertussis in adolescents (10 years and older) and adults, Pertussis protection in pregnant women (to provide passive immunity to infants).
At a glance
| Generic name | Boostrix TM |
|---|---|
| Also known as | dTpa vaccine |
| Sponsor | GlaxoSmithKline |
| Drug class | Combination vaccine (toxoid and acellular pertussis) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Boostrix contains inactivated toxoids of diphtheria and tetanus, along with acellular pertussis antigens, which trigger adaptive immune responses. Upon vaccination, the immune system generates specific antibodies and cellular immunity against these three bacterial pathogens, providing protection against infection and disease. The vaccine is administered as a booster dose to maintain or restore immunity in adolescents and adults.
Approved indications
- Booster vaccination against diphtheria, tetanus, and pertussis in adolescents (10 years and older) and adults
- Pertussis protection in pregnant women (to provide passive immunity to infants)
Common side effects
- Injection site pain, redness, or swelling
- Headache
- Fatigue
- Myalgia (muscle pain)
- Fever
Key clinical trials
- Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults (PHASE2)
- Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Children in Russia (PHASE4)
- Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6-12wks of Age (PHASE3)
- Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents (PHASE4)
- Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects (PHASE3)
- Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects (PHASE3)
- Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children. (PHASE3)
- Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Boostrix TM CI brief — competitive landscape report
- Boostrix TM updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI